american diabetes association pancreatitis history glp-1 receptor agonist Frontiers Glucagon-like peptide-1 receptor agonists and
Description
doi: 10.1093/jn/nxab029
Average total body weight loss (TBWL) after one year on a GLP-1 semaglutide such as Wegovy and Ozempic is 12%15%, and on a GLP-1 tirzepatide like Mounjaro, & Zepbound is 21%
The Nurse Practitioner, 51(5), 22-30
With dual and triple agonists, clinical studies are now achieving results that are otherwise only known from bariatric surgery
Retrieved from Rodriguez, P
A summary of clinical studies elucidating the use of antidiabetics against glaucoma is given in Table 2
